{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:09:09Z","timestamp":1790762949531,"version":"4.1.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41574-026-01260-x","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:48:29Z","timestamp":1779292109000},"page":"490-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The pathogenesis and intersecting mechanisms of monogenic bone mass disorders"],"prefix":"10.1038","volume":"22","author":[{"given":"Raja","family":"Padidela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-9241","authenticated-orcid":false,"given":"Gretl","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9871-4578","authenticated-orcid":false,"given":"Geert","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-001X","authenticated-orcid":false,"given":"Outi","family":"M\u00e4kitie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"1260_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nrrheum.2015.48","volume":"11","author":"G Hendrickx","year":"2015","unstructured":"Hendrickx, G., Boudin, E. & Van Hul, W. A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat. Rev. Rheumatol. 11, 462\u2013474 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1260_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, therapy. JAMA 285, 785\u2013795 (2001).","journal-title":"JAMA"},{"key":"1260_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbmr.4715","volume":"38","author":"DJM Bergen","year":"2020","unstructured":"Bergen, D. J. M. et al. High bone mass disorders: new insights from connecting the clinic and the bench. J. Bone Miner. Res. 38, 229\u2013247 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/JCD:8:1:001","volume":"8","author":"MP Whyte","year":"2005","unstructured":"Whyte, M. P. Misinterpretation of osteodensitometry with high bone density: BMD Z \u2265+2.5 is not \u201cnormal\u201d. J. Clin. Densitom. 8, 1\u20136 (2005).","journal-title":"J. Clin. Densitom."},{"key":"1260_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1172\/JCI113125","volume":"80","author":"NA Pocock","year":"1987","unstructured":"Pocock, N. A. et al. Genetic determinants of bone mass in adults. A twin study. J. Clin. Invest. 80, 706\u2013710 (1987).","journal-title":"J. Clin. Invest."},{"key":"1260_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41588-018-0302-x","volume":"51","author":"JA Morris","year":"2019","unstructured":"Morris, J. A. et al. An atlas of genetic influences on osteoporosis in humans and mice. Nat. Genet. 51, 258\u2013266 (2019).","journal-title":"Nat. Genet."},{"key":"1260_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ajmg.a.63132","volume":"191","author":"S Unger","year":"2023","unstructured":"Unger, S. et al. Nosology of genetic skeletal disorders: 2023 revision. Am. J. Med. Genet. A 191, 1164\u20131209 (2023).","journal-title":"Am. J. Med. Genet. A"},{"key":"1260_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00165","volume":"11","author":"Y Huybrechts","year":"2020","unstructured":"Huybrechts, Y., Mortier, G., Boudin, E. & Van Hul, W. WNT signaling and bone: lessons from skeletal dysplasias and disorders. Front. Endocrinol.11, 165 (2020).","journal-title":"Front. Endocrinol."},{"key":"1260_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/35035110","volume":"407","author":"M Wehrli","year":"2000","unstructured":"Wehrli, M. et al. arrow encodes an LDL-receptor-related protein essential for wingless signalling. Nature 407, 527\u2013530 (2000).","journal-title":"Nature"},{"key":"1260_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/382225a0","volume":"382","author":"P Bhanot","year":"1996","unstructured":"Bhanot, P. et al. A new member of the frizzled family from Drosophila functions as a wingless receptor. Nature 382, 225\u2013230 (1996).","journal-title":"Nature"},{"key":"1260_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/ajmg.a.61119","volume":"179","author":"S Nampoothiri","year":"2019","unstructured":"Nampoothiri, S. et al. Ptosis as a unique hallmark for autosomal recessive WNT1-associated osteogenesis imperfecta. Am. J. Med. Genet. A 179, 908\u2013914 (2019).","journal-title":"Am. J. Med. Genet. A"},{"key":"1260_CR12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1215458","volume":"368","author":"CM Laine","year":"2013","unstructured":"Laine, C. M. et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N. Engl. J. Med. 368, 1809\u20131816 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/jbmr.3680","volume":"34","author":"F Wang","year":"2019","unstructured":"Wang, F. et al. Mesenchymal cell-derived juxtacrine wnt1 signaling regulates osteoblast activity and osteoclast differentiation. J. Bone Miner. Res. 34, 1129\u20131142 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ajhg.2013.02.010","volume":"92","author":"K Keupp","year":"2013","unstructured":"Keupp, K. et al. Mutations in WNT1 cause different forms of bone fragility. Am. J. Hum. Genet. 92, 565\u2013574 (2013).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1399-0004.1984.tb00481.x","volume":"25","author":"P Beighton","year":"1984","unstructured":"Beighton, P., Barnard, A., Hamersma, H. & van der Wouden, A. The syndromic status of sclerosteosis and van Buchem disease. Clin. Genet. 25, 175\u2013181 (1984).","journal-title":"Clin. Genet."},{"key":"1260_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577\u2013589 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR17","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li, X. et al. Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883\u201319887 (2005).","journal-title":"J. Biol. Chem."},{"key":"1260_CR18","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","volume":"286","author":"O Leupin","year":"2011","unstructured":"Leupin, O. et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J. Biol. Chem. 286, 19489\u201319500 (2011).","journal-title":"J. Biol. Chem."},{"key":"1260_CR19","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1101\/gr.3437105","volume":"15","author":"GG Loots","year":"2005","unstructured":"Loots, G. G. et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 15, 928\u2013935 (2005).","journal-title":"Genome Res."},{"key":"1260_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00439-011-0947-3","volume":"129","author":"SJ Kim","year":"2011","unstructured":"Kim, S. J. et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum. Genet. 129, 497\u2013502 (2011).","journal-title":"Hum. Genet."},{"key":"1260_CR21","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1056\/NEJMoa1509342","volume":"374","author":"POS Kiper","year":"2016","unstructured":"Kiper, P. O. S. et al. Cortical-bone fragility \u2014 insights from sFRP4 deficiency in Pyle\u2019s disease. N. Engl. J. Med. 374, 2553\u20132562 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.593407","volume":"11","author":"A Sowi\u0144ska-Seidler","year":"2020","unstructured":"Sowi\u0144ska-Seidler, A. et al. The first report of biallelic missense mutations in the SFRP4 gene causing Pyle disease in two siblings. Front. Genet. 11, 593407 (2020).","journal-title":"Front. Genet."},{"key":"1260_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"Y Gong","year":"2001","unstructured":"Gong, Y. et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513\u2013523 (2001).","journal-title":"Cell"},{"key":"1260_CR24","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1210\/en.2006-1352","volume":"148","author":"W Balemans","year":"2007","unstructured":"Balemans, W. & Van Hul, W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology 148, 2622\u20132629 (2007).","journal-title":"Endocrinology"},{"key":"1260_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00223-008-9130-9","volume":"82","author":"W Balemans","year":"2008","unstructured":"Balemans, W. et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif. Tissue Int. 82, 445\u2013453 (2008).","journal-title":"Calcif. Tissue Int."},{"key":"1260_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.bone.2019.05.003","volume":"127","author":"MP Whyte","year":"2019","unstructured":"Whyte, M. P. et al. New explanation for autosomal dominant high bone mass: mutation of low-density lipoprotein receptor-related protein 6. Bone 127, 228\u2013243 (2019).","journal-title":"Bone"},{"key":"1260_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/338450","volume":"70","author":"RD Little","year":"2002","unstructured":"Little, R. D. et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11\u201319 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR28","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/nsmb.2139","volume":"18","author":"Z Cheng","year":"2011","unstructured":"Cheng, Z. et al. Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat. Struct. Mol. Biol. 18, 1204\u20131210 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1260_CR29","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/hmg\/ddt578","volume":"23","author":"B Ohkawara","year":"2014","unstructured":"Ohkawara, B. et al. LRP4 third \u03b2-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner. Hum. Mol. Genet. 23, 1856\u20131868 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1260_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/genes13010080","volume":"13","author":"Y Huybrechts","year":"2021","unstructured":"Huybrechts, Y. et al. Identification of compound heterozygous variants in LRP4 demonstrates that a pathogenic variant outside the third \u03b2-propeller domain can cause sclerosteosis. Genes 13, 80 (2021).","journal-title":"Genes"},{"key":"1260_CR31","doi-asserted-by":"publisher","first-page":"24735","DOI":"10.1074\/jbc.272.40.24735","volume":"272","author":"K Orford","year":"1997","unstructured":"Orford, K., Crockett, C., Jensen, J. P., Weissman, A. M. & Byers, S. W. Serine phosphorylation-regulated ubiquitination and degradation of \u03b2-catenin. J. Biol. Chem. 272, 24735\u201324738 (1997).","journal-title":"J. Biol. Chem."},{"key":"1260_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/jbmr.3387","volume":"33","author":"G Comai","year":"2018","unstructured":"Comai, G. et al. Genetic and molecular insights into genotype-phenotype relationships in osteopathia striata with cranial sclerosis (OSCS) through the analysis of novel mouse Wtx mutant alleles. J. Bone Miner. Res. 33, 875\u2013887 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1359\/jbmr.090707","volume":"25","author":"B Perdu","year":"2010","unstructured":"Perdu, B. et al. Osteopathia striata with cranial sclerosis owing to WTX gene defect. J. Bone Miner. Res. 25, 82\u201390 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR34","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.ajhg.2023.07.011","volume":"110","author":"P Terhal","year":"2023","unstructured":"Terhal, P. et al. AXIN1 bi-allelic variants disrupting the C-terminal DIX domain cause craniometadiaphyseal osteosclerosis with hip dysplasia. Am. J. Hum. Genet. 110, 1470\u20131481 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa034","volume":"105","author":"H Peng","year":"2020","unstructured":"Peng, H. et al. An activating variant in CTNNB1 is associated with a sclerosing bone dysplasia and adrenocortical neoplasia. J. Clin. Endocrinol. Metab. 105, dgaa034 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1260_CR36","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1210\/clinem\/dgad757","volume":"109","author":"Y Huybrechts","year":"2024","unstructured":"Huybrechts, Y. et al. A mosaic variant in CTNNB1\/\u03b2-catenin as a novel cause for osteopathia striata with cranial sclerosis. J. Clin. Endocrinol. Metab. 109, 1891\u20131898 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1260_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ajhg.2015.02.010","volume":"96","author":"KJ Bunn","year":"2015","unstructured":"Bunn, K. J. et al. Mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. Am. J. Hum. Genet. 96, 623\u2013630 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR38","first-page":"281","volume":"14","author":"HD Rott","year":"2003","unstructured":"Rott, H. D., Krieg, P., R\u00fctschle, H. & Kraus, C. Multiple malformations in a male and maternal osteopathia strata with cranial sclerosis (OSCS). Genet. Couns. 14, 281\u2013288 (2003).","journal-title":"Genet. Couns."},{"key":"1260_CR39","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science\/1141515","volume":"316","author":"MB Major","year":"2007","unstructured":"Major, M. B. et al. Wilms tumor suppressor WTX negatively regulates WNT\/\u03b2-catenin signaling. Science 316, 1043\u20131046 (2007).","journal-title":"Science"},{"key":"1260_CR40","doi-asserted-by":"publisher","first-page":"19204","DOI":"10.1074\/jbc.M111.224881","volume":"286","author":"K Tanneberger","year":"2011","unstructured":"Tanneberger, K. et al. Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1 (Amer1). J. Biol. Chem. 286, 19204\u201319214 (2011).","journal-title":"J. Biol. Chem."},{"key":"1260_CR41","unstructured":"Gear, R. & Savarirayan, R. in GeneReviews(eds Adam, M. P. et al.) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK569515\/ (Univ. Washington, Seattle, 2023)."},{"key":"1260_CR42","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/79039","volume":"7","author":"JP von Kries","year":"2000","unstructured":"von Kries, J. P. et al. Hot spots in \u03b2-catenin for interactions with LEF-1, conductin and APC. Nat. Struct. Biol. 7, 800\u2013807 (2000).","journal-title":"Nat. Struct. Biol."},{"key":"1260_CR43","doi-asserted-by":"publisher","first-page":"E419","DOI":"10.1210\/jc.2010-1885","volume":"96","author":"S Bonnet","year":"2011","unstructured":"Bonnet, S. et al. Wnt\/\u03b2-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J. Clin. Endocrinol. Metab. 96, E419\u2013E426 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1260_CR44","first-page":"8","volume":"42","author":"S Kim","year":"2019","unstructured":"Kim, S. & Jeong, S. Mutation hotspots in the \u03b2-catenin gene: lessons from the human cancer genome databases. Mol. Cell 42, 8\u201316 (2019).","journal-title":"Mol. Cell"},{"key":"1260_CR45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nsmb1247","volume":"14","author":"T Schwarz-Romond","year":"2007","unstructured":"Schwarz-Romond, T. et al. The DIX domain of dishevelled confers Wnt signaling by dynamic polymerization. Nat. Struct. Mol. Biol. 14, 484\u2013492 (2007).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1260_CR46","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ajhg.2015.02.015","volume":"96","author":"J White","year":"2015","unstructured":"White, J. et al. DVL1 frameshift mutations clustering in the penultimate exon cause autosomal-dominant Robinow syndrome. Am. J. Hum. Genet. 96, 612\u2013622 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR47","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1210\/er.2004-0001","volume":"26","author":"K Janssens","year":"2005","unstructured":"Janssens, K., ten Dijke, P., Janssens, S. & Van Hul, W. Transforming growth factor-\u03b21 to the bone. Endocr. Rev. 26, 743\u2013774 (2005).","journal-title":"Endocr. Rev."},{"key":"1260_CR48","doi-asserted-by":"publisher","first-page":"272","DOI":"10.7150\/ijbs.2929","volume":"8","author":"G Chen","year":"2012","unstructured":"Chen, G., Deng, C. & Li, Y.-P. TGF-\u03b2 and BMP signaling in osteoblast differentiation and bone formation. Int. J. Biol. Sci. 8, 272\u2013288 (2012).","journal-title":"Int. J. Biol. Sci."},{"key":"1260_CR49","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1242\/dev.126.19.4267","volume":"126","author":"E Filvaroff","year":"1999","unstructured":"Filvaroff, E. et al. Inhibition of TGF-\u03b2 receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126, 4267\u20134279 (1999).","journal-title":"Development"},{"key":"1260_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/boneres.2016.9","volume":"4","author":"M Wu","year":"2016","unstructured":"Wu, M., Chen, G. & Li, Y.-P. TGF-\u03b2 and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 4, 16009 (2016).","journal-title":"Bone Res."},{"key":"1260_CR51","doi-asserted-by":"publisher","first-page":"7718","DOI":"10.1074\/jbc.M208857200","volume":"278","author":"K Janssens","year":"2003","unstructured":"Janssens, K., ten Dijke, P., Ralston, S. H., Bergmann, C. & Van Hul, W. Transforming growth factor-\u03b21 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J. Biol. Chem. 278, 7718\u20137724 (2003).","journal-title":"J. Biol. Chem."},{"key":"1260_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1006\/geno.2000.6192","volume":"66","author":"SP Vaughn","year":"2000","unstructured":"Vaughn, S. P. et al. Confirmation of the mapping of the Camurati-Englemann locus to 19q13. 2 and refinement to a 3.2-cM region. Genomics 66, 119\u2013121 (2000).","journal-title":"Genomics"},{"key":"1260_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/79128","volume":"26","author":"A Kinoshita","year":"2000","unstructured":"Kinoshita, A. et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat. Genet. 26, 19\u201320 (2000).","journal-title":"Nat. Genet."},{"key":"1260_CR54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s10038-024-01274-1","volume":"69","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Heterozygous mutations in the straitjacket region of the latency-associated peptide domain of TGFB2 cause Camurati-Engelmann disease type II. J. Hum. Genet. 69, 599\u2013605 (2024).","journal-title":"J. Hum. Genet."},{"key":"1260_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117477","volume":"197","author":"S Mumm","year":"2025","unstructured":"Mumm, S. et al. Transforming growth factor, beta-2 gene mutation causes autosomal dominant Camurati-Engelmann disease, type 2 (OMIM % 606631). Bone 197, 117477 (2025).","journal-title":"Bone"},{"key":"1260_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/srep07596","volume":"4","author":"S Tsukamoto","year":"2014","unstructured":"Tsukamoto, S. et al. Smad9 is a new type of transcriptional regulator in bone morphogenetic protein signaling. Sci. Rep. 4, 7596 (2014).","journal-title":"Sci. Rep."},{"key":"1260_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/jbmr.3875","volume":"35","author":"CL Gregson","year":"2020","unstructured":"Gregson, C. L. et al. A rare mutation in SMAD9 associated with high bone mass identifies the SMAD-dependent BMP signaling pathway as a potential anabolic target for osteoporosis. J. Bone Miner. Res. 35, 92\u2013105 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191499","volume":"217","author":"H Kang","year":"2020","unstructured":"Kang, H. et al. Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-\u03b2\/SMAD pathway. J. Exp. Med. 217, e20191499 (2020).","journal-title":"J. Exp. Med."},{"key":"1260_CR59","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/j.1399-0004.2009.01177.x","volume":"75","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y., Castori, M., Ferranti, G., Paradisi, M. & Wordsworth, B. P. Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis. Clin. Genet. 75, 556\u2013561 (2009).","journal-title":"Clin. Genet."},{"key":"1260_CR60","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/ng1453","volume":"36","author":"J Hellemans","year":"2004","unstructured":"Hellemans, J. et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat. Genet. 36, 1213\u20131218 (2004).","journal-title":"Nat. Genet."},{"key":"1260_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22340-8","volume":"12","author":"L Guo","year":"2021","unstructured":"Guo, L. et al. Deficiency of TMEM53 causes a previously unknown sclerosing bone disorder by dysregulation of BMP-SMAD signaling. Nat. Commun. 12, 2046 (2021).","journal-title":"Nat. Commun."},{"key":"1260_CR62","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41574-024-01039-y","volume":"21","author":"S Melis","year":"2025","unstructured":"Melis, S., Trompet, D., Chagin, A. S. & Maes, C. Skeletal stem and progenitor cells in bone physiology, ageing and disease. Nat. Rev. Endocrinol. 21, 135\u2013153 (2025).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1260_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","volume":"108","author":"K Nakashima","year":"2002","unstructured":"Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17\u201329 (2002).","journal-title":"Cell"},{"key":"1260_CR64","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0092-8674(00)80259-7","volume":"89","author":"F Otto","year":"1997","unstructured":"Otto, F. et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89, 765\u2013771 (1997).","journal-title":"Cell"},{"key":"1260_CR65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","volume":"87","author":"P Lapunzina","year":"2010","unstructured":"Lapunzina, P. et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am. J. Hum. Genet. 87, 110\u2013114 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116400","volume":"160","author":"K Ludwig","year":"2022","unstructured":"Ludwig, K. et al. Dominant osteogenesis imperfecta with low bone turnover caused by a heterozygous SP7 variant. Bone 160, 116400 (2022).","journal-title":"Bone"},{"key":"1260_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115364","volume":"137","author":"MP Whyte","year":"2020","unstructured":"Whyte, M. P. et al. Juvenile Paget\u2019s disease from heterozygous mutation of SP7 encoding osterix (specificity protein 7, transcription factor SP7). Bone 137, 115364 (2020).","journal-title":"Bone"},{"key":"1260_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116633","volume":"167","author":"G Hendrickx","year":"2023","unstructured":"Hendrickx, G. et al. A recessive form of craniodiaphyseal dysplasia caused by a homozygous missense variant in SP7\/Osterix. Bone 167, 116633 (2023).","journal-title":"Bone"},{"key":"1260_CR69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence, D. O., Senn, A. & Danks, D. M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 16, 101\u2013116 (1979).","journal-title":"J. Med. Genet."},{"key":"1260_CR70","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/bmj.1.5905.421","volume":"1","author":"MJ Francis","year":"1974","unstructured":"Francis, M. J., Smith, R. & Bauze, R. J. Instability of polymeric skin collagen in osteogenesis imperfecta. Br. Med. J. 1, 421\u2013424 (1974).","journal-title":"Br. Med. J."},{"key":"1260_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0167-4889(86)90005-4","volume":"889","author":"J Bonaventure","year":"1986","unstructured":"Bonaventure, J., Cohen-Solal, L., Lasselin, C., Allain, J.-C. & Maroteaux, P. Abnormal procollagen synthesis in fibroblasts from three patients of the same family with a severe form of osteogenesis imperfecta (type III). Biochim. Biophys. Acta 889, 23\u201334 (1986).","journal-title":"Biochim. Biophys. Acta"},{"key":"1260_CR72","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1073\/pnas.78.8.5142","volume":"78","author":"GS Barsh","year":"1981","unstructured":"Barsh, G. S. & Byers, P. H. Reduced secretion of structurally abnormal type I procollagen in a form of osteogenesis imperfecta. Proc. Natl Acad. Sci. USA 78, 5142\u20135146 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1260_CR73","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1172\/JCI22760","volume":"115","author":"RC Gensure","year":"2005","unstructured":"Gensure, R. C. et al. A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J. Clin. Invest. 115, 1250\u20131257 (2005).","journal-title":"J. Clin. Invest."},{"key":"1260_CR74","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bone.2013.12.030","volume":"60","author":"H Nistala","year":"2014","unstructured":"Nistala, H., M\u00e4kitie, O. & J\u00fcppner, H. Caffey disease: new perspectives on old questions. Bone 60, 246\u2013251 (2014).","journal-title":"Bone"},{"key":"1260_CR75","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/humu.21647","volume":"33","author":"V Mart\u00ednez-Glez","year":"2012","unstructured":"Mart\u00ednez-Glez, V. et al. Identification of a mutation causing deficient BMP1\/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum. Mutat. 33, 343\u2013350 (2012).","journal-title":"Hum. Mutat."},{"key":"1260_CR76","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ajhg.2012.02.026","volume":"90","author":"PV Asharani","year":"2012","unstructured":"Asharani, P. V. et al. Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. Am. J. Hum. Genet. 90, 661\u2013674 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR77","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1002\/ajmg.a.37958","volume":"170","author":"RC Pollitt","year":"2016","unstructured":"Pollitt, R. C. et al. Phenotypic variability in patients with osteogenesis imperfecta caused by BMP1 mutations. Am. J. Med. Genet. A 170, 3150\u20133156 (2016).","journal-title":"Am. J. Med. Genet. A"},{"key":"1260_CR78","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/humu.21475","volume":"32","author":"K Lindahl","year":"2011","unstructured":"Lindahl, K. et al. COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Hum. Mutat. 32, 598\u2013609 (2011).","journal-title":"Hum. Mutat."},{"key":"1260_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/polym13162642","volume":"13","author":"R Naomi","year":"2021","unstructured":"Naomi, R., Ridzuan, P. M. & Bahari, H. Current insights into collagen type I. Polymers 13, 2642 (2021).","journal-title":"Polymers"},{"key":"1260_CR80","doi-asserted-by":"publisher","first-page":"17641","DOI":"10.1074\/jbc.M109.007070","volume":"284","author":"Y Ishikawa","year":"2009","unstructured":"Ishikawa, Y., Wirz, J., Vranka, J. A., Nagata, K. & B\u00e4chinger, H. P. Biochemical characterization of the prolyl 3-hydroxylase 1.cartilage-associated protein.cyclophilin B complex. J. Biol. Chem. 284, 17641\u201317647 (2009).","journal-title":"J. Biol. Chem."},{"key":"1260_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004465","volume":"10","author":"WA Cabral","year":"2014","unstructured":"Cabral, W. A. et al. Abnormal type I collagen post-translational modification and crosslinking in a cyclophilin B KO mouse model of recessive osteogenesis imperfecta. PLoS Genet. 10, e1004465 (2014).","journal-title":"PLoS Genet."},{"key":"1260_CR82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","volume":"31","author":"LM Ward","year":"2002","unstructured":"Ward, L. M. et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31, 12\u201318 (2002).","journal-title":"Bone"},{"key":"1260_CR83","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.4161\/cc.6.14.4474","volume":"6","author":"JC Marini","year":"2007","unstructured":"Marini, J. C., Cabral, W. A., Barnes, A. M. & Chang, W. Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development. Cell Cycle 6, 1675\u20131681 (2007).","journal-title":"Cell Cycle"},{"key":"1260_CR84","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1248\/bpb.b16-00612","volume":"39","author":"A Ichimura","year":"2016","unstructured":"Ichimura, A. & Takeshima, H. TRIC-B mutations causing osteogenesis imperfecta. Biol. Pharm. Bull. 39, 1743\u20131747 (2016).","journal-title":"Biol. Pharm. Bull."},{"key":"1260_CR85","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/jmedgenet-2012-101142","volume":"49","author":"R Shaheen","year":"2012","unstructured":"Shaheen, R. et al. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. J. Med. Genet. 49, 630\u2013635 (2012).","journal-title":"J. Med. Genet."},{"key":"1260_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006156","volume":"12","author":"WA Cabral","year":"2016","unstructured":"Cabral, W. A. et al. Absence of the ER cation channel TMEM38B\/TRIC-B disrupts intracellular calcium homeostasis and dysregulates collagen synthesis in recessive osteogenesis imperfecta. PLoS Genet. 12, e1006156 (2016).","journal-title":"PLoS Genet."},{"key":"1260_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1009339","volume":"17","author":"D Syx","year":"2021","unstructured":"Syx, D. et al. Aberrant binding of mutant HSP47 affects posttranslational modification of type I collagen and leads to osteogenesis imperfecta. PLoS Genet. 17, e1009339 (2021).","journal-title":"PLoS Genet."},{"key":"1260_CR88","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","volume":"86","author":"HE Christiansen","year":"2010","unstructured":"Christiansen, H. E. et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am. J. Hum. Genet. 86, 389\u2013398 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR89","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nrm3588","volume":"14","author":"F Brandizzi","year":"2013","unstructured":"Brandizzi, F. & Barlowe, C. Organization of the ER-Golgi interface for membrane traffic control. Nat. Rev. Mol. Cell Biol. 14, 382\u2013392 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1260_CR90","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.ajhg.2021.08.002","volume":"108","author":"R Marom","year":"2021","unstructured":"Marom, R. et al. COPB2 loss of function causes a coatopathy with osteoporosis and developmental delay. Am. J. Hum. Genet. 108, 1710\u20131724 (2021).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/srep37374","volume":"6","author":"F Rodriguez-Pascual","year":"2016","unstructured":"Rodriguez-Pascual, F. & Slatter, D. A. Collagen cross-linking: insights on the evolution of metazoan extracellular matrix. Sci. Rep. 6, 37374 (2016).","journal-title":"Sci. Rep."},{"key":"1260_CR92","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ajhg.2010.02.022","volume":"86","author":"Y Alanay","year":"2010","unstructured":"Alanay, Y. et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am. J. Hum. Genet. 86, 551\u2013559 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR93","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajhg.2010.05.020","volume":"87","author":"R Shaheen","year":"2010","unstructured":"Shaheen, R., Al-Owain, M., Sakati, N., Alzayed, Z. S. & Alkuraya, F. S. FKBP10 and Bruck syndrome: phenotypic heterogeneity or call for reclassification? Am. J. Hum. Genet. 87, 306\u2013307 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR94","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/humu.22362","volume":"34","author":"AM Barnes","year":"2013","unstructured":"Barnes, A. M. et al. Kuskokwim syndrome, a recessive congenital contracture disorder, extends the phenotype of FKBP10 mutations. Hum. Mutat. 34, 1279\u20131288 (2013).","journal-title":"Hum. Mutat."},{"key":"1260_CR95","doi-asserted-by":"publisher","first-page":"40967","DOI":"10.1074\/jbc.M307380200","volume":"278","author":"AJ van der Slot","year":"2003","unstructured":"van der Slot, A. J. et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J. Biol. Chem. 278, 40967\u201340972 (2003).","journal-title":"J. Biol. Chem."},{"key":"1260_CR96","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2741\/1576","volume":"10","author":"HC Anderson","year":"2005","unstructured":"Anderson, H. C., Garimella, R. & Tague, S. E. The role of matrix vesicles in growth plate development and biomineralization. Front. Biosci. 10, 822\u2013837 (2005).","journal-title":"Front. Biosci."},{"key":"1260_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0869-4","volume":"13","author":"AB Daniel","year":"2018","unstructured":"Daniel, A. B. et al. Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations. Orphanet J. Rare Dis. 13, 142 (2018).","journal-title":"Orphanet J. Rare Dis."},{"key":"1260_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01483-9","volume":"15","author":"R Padidela","year":"2020","unstructured":"Padidela, R. et al. Characterization of tracheobronchomalacia in infants with hypophosphatasia. Orphanet J. Rare Dis. 15, 204 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"1260_CR99","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte, M. P. Hypophosphatasia \u2014 aetiology, nosology, pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 12, 233\u2013246 (2016).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1260_CR100","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/jbmr.4418","volume":"36","author":"CR Ferreira","year":"2021","unstructured":"Ferreira, C. R. et al. Ectopic calcification and hypophosphatemic rickets: natural history of ENPP1 and ABCC6 deficiencies. J. Bone Miner. Res. 36, 2193\u20132202 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR101","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1210\/en.2002-220454","volume":"143","author":"MM Donohue","year":"2002","unstructured":"Donohue, M. M. & Demay, M. B. Rickets in VDR null mice is secondary to decreased apoptosis of hypertrophic chondrocytes. Endocrinology 143, 3691\u20133694 (2002).","journal-title":"Endocrinology"},{"key":"1260_CR102","doi-asserted-by":"publisher","first-page":"9637","DOI":"10.1073\/pnas.0502249102","volume":"102","author":"Y Sabbagh","year":"2005","unstructured":"Sabbagh, Y., Carpenter, T. O. & Demay, M. B. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc. Natl Acad. Sci. USA 102, 9637\u20139642 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1260_CR103","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1073\/pnas.0402490101","volume":"101","author":"JB Cheng","year":"2004","unstructured":"Cheng, J. B., Levine, M. A., Bell, N. H., Mangelsdorf, D. J. & Russell, D. W. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl Acad. Sci. USA 101, 7711\u20137715 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1260_CR104","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1126\/science.2849209","volume":"242","author":"MR Hughes","year":"1988","unstructured":"Hughes, M. R. et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 242, 1702\u20131705 (1988).","journal-title":"Science"},{"key":"1260_CR105","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1172\/JCI98680","volume":"128","author":"JD Roizen","year":"2018","unstructured":"Roizen, J. D. et al. CYP3A4 mutation causes vitamin D-dependent rickets type 3. J. Clin. Invest. 128, 1913\u20131918 (2018).","journal-title":"J. Clin. Invest."},{"key":"1260_CR106","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1359\/jbmr.1997.12.10.1552","volume":"12","author":"R St-Arnaud","year":"1997","unstructured":"St-Arnaud, R., Messerlian, S., Moir, J. M., Omdahl, J. L. & Glorieux, F. H. The 25-hydroxyvitamin D 1-\u03b1-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J. Bone Miner. Res. 12, 1552\u20131559 (1997).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR107","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0169-6009(91)90038-2","volume":"12","author":"MB Oliveri","year":"1991","unstructured":"Oliveri, M. B., Cassinelli, H., Bergad\u00e1, C. & Mautalen, C. A. Bone mineral density of the spine and radius shaft in children with X-linked hypophosphatemic rickets (XLH). Bone Min. 12, 91\u2013100 (1991).","journal-title":"Bone Min."},{"key":"1260_CR108","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","volume":"91","author":"T-J Cho","year":"2012","unstructured":"Cho, T.-J. et al. A single recurrent mutation in the 5\u2019-UTR of IFITM5 causes osteogenesis imperfecta type V. Am. J. Hum. Genet. 91, 343\u2013348 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR109","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s00198-016-3709-1","volume":"27","author":"G Bardai","year":"2016","unstructured":"Bardai, G., Moffatt, P., Glorieux, F. H. & Rauch, F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. Osteoporos. Int. 27, 3607\u20133613 (2016).","journal-title":"Osteoporos. Int."},{"key":"1260_CR110","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/jmedgenet-2012-101307","volume":"50","author":"F Rauch","year":"2013","unstructured":"Rauch, F. et al. Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients. J. Med. Genet. 50, 21\u201324 (2013).","journal-title":"J. Med. Genet."},{"key":"1260_CR111","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","volume":"15","author":"FH Glorieux","year":"2000","unstructured":"Glorieux, F. H. et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J. Bone Miner. Res. 15, 1650\u20131658 (2000).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR112","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/jbmr.1983","volume":"28","author":"M Grover","year":"2013","unstructured":"Grover, M. et al. Osteogenesis imperfecta without features of type V caused by a mutation in the IFITM5 gene. J. Bone Miner. Res. 28, 2333\u20132337 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR113","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/jbmr.2156","volume":"29","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn, H. et al. A nonclassical IFITM5 mutation located in the coding region causes severe osteogenesis imperfecta with prenatal onset. J. Bone Miner. Res. 29, 1387\u20131391 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR114","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/stem.1505","volume":"31","author":"F Li","year":"2013","unstructured":"Li, F., Song, N., Tombran-Tink, J. & Niyibizi, C. Pigment epithelium-derived factor enhances differentiation and mineral deposition of human mesenchymal stem cells. Stem Cell 31, 2714\u20132723 (2013).","journal-title":"Stem Cell"},{"key":"1260_CR115","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/jbmr.1892","volume":"28","author":"R Bogan","year":"2013","unstructured":"Bogan, R. et al. A mouse model for human osteogenesis imperfecta type VI. J. Bone Miner. Res. 28, 1531\u20131536 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR116","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux, F. H. et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J. Bone Miner. Res. 17, 30\u201338 (2002).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-008-9196-4","volume":"84","author":"A Villa","year":"2009","unstructured":"Villa, A., Guerrini, M. M., Cassani, B., Pangrazio, A. & Sobacchi, C. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif. Tissue Int. 84, 1\u201312 (2009).","journal-title":"Calcif. Tissue Int."},{"key":"1260_CR118","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrendo.2013.137","volume":"9","author":"C Sobacchi","year":"2013","unstructured":"Sobacchi, C., Schulz, A., Coxon, F. P., Villa, A. & Helfrich, M. H. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat. Rev. Endocrinol. 9, 522\u2013536 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1260_CR119","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1365-2990.2003.00474.x","volume":"29","author":"CG Steward","year":"2003","unstructured":"Steward, C. G. Neurological aspects of osteopetrosis. Neuropathol. Appl. Neurobiol. 29, 87\u201397 (2003).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1260_CR120","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bone.2007.08.029","volume":"42","author":"A Del Fattore","year":"2008","unstructured":"Del Fattore, A., Cappariello, A. & Teti, A. Genetics, pathogenesis and complications of osteopetrosis. Bone 42, 19\u201329 (2008).","journal-title":"Bone"},{"key":"1260_CR121","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11914-018-0439-7","volume":"16","author":"R De Ridder","year":"2018","unstructured":"De Ridder, R., Boudin, E., Mortier, G. & Van Hul, W. Human genetics of sclerosing bone disorders. Curr. Osteoporos. Rep. 16, 256\u2013268 (2018).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1260_CR122","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/ng2076","volume":"39","author":"C Sobacchi","year":"2007","unstructured":"Sobacchi, C. et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 39, 960\u2013962 (2007).","journal-title":"Nat. Genet."},{"key":"1260_CR123","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajhg.2008.06.015","volume":"83","author":"MM Guerrini","year":"2008","unstructured":"Guerrini, M. M. et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet. 83, 64\u201376 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR124","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/71667","volume":"24","author":"AE Hughes","year":"2000","unstructured":"Hughes, A. E. et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24, 45\u201348 (2000).","journal-title":"Nat. Genet."},{"key":"1260_CR125","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/77131","volume":"25","author":"A Frattini","year":"2000","unstructured":"Frattini, A. et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat. Genet. 25, 343\u2013346 (2000).","journal-title":"Nat. Genet."},{"key":"1260_CR126","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/sj.bmt.1704194","volume":"32","author":"GJA Driessen","year":"2003","unstructured":"Driessen, G. J. A. et al. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transpl. 32, 657\u2013663 (2003).","journal-title":"Bone Marrow Transpl."},{"key":"1260_CR127","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bone.2018.12.002","volume":"120","author":"A Howaldt","year":"2019","unstructured":"Howaldt, A. et al. Sclerosing bone dysplasias with hallmarks of dysosteosclerosis in four patients carrying mutations in SLC29A3 and TCIRG1. Bone 120, 495\u2013503 (2019).","journal-title":"Bone"},{"key":"1260_CR128","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1172\/JCI117235","volume":"93","author":"T Laitala","year":"1994","unstructured":"Laitala, T. & V\u00e4\u00e4n\u00e4nen, H. K. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H+-ATPase. J. Clin. Invest. 93, 2311\u20132318 (1994).","journal-title":"J. Clin. Invest."},{"key":"1260_CR129","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1073\/pnas.80.9.2752","volume":"80","author":"WS Sly","year":"1983","unstructured":"Sly, W. S., Hewett-Emmett, D., Whyte, M. P., Yu, Y. S. & Tashian, R. E. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc. Natl Acad. Sci. USA 80, 2752\u20132756 (1983).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1260_CR130","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1073\/pnas.89.5.1804","volume":"89","author":"DE Roth","year":"1992","unstructured":"Roth, D. E., Venta, P. J., Tashian, R. E. & Sly, W. S. Molecular basis of human carbonic anhydrase II deficiency. Proc. Natl Acad. Sci. USA 89, 1804\u20131808 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1260_CR131","first-page":"1082","volume":"49","author":"PJ Venta","year":"1991","unstructured":"Venta, P. J., Welty, R. J., Johnson, T. M., Sly, W. S. & Tashian, R. E. Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His\u2013Tyr): complete structure of the normal human CA II gene. Am. J. Hum. Genet. 49, 1082\u20131090 (1991).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR132","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1093\/hmg\/10.25.2861","volume":"10","author":"E Cleiren","year":"2001","unstructured":"Cleiren, E. et al. Albers-Sch\u00f6nberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum. Mol. Genet. 10, 2861\u20132867 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"1260_CR133","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature04535","volume":"440","author":"PF Lange","year":"2006","unstructured":"Lange, P. F., Wartosch, L., Jentsch, T. J. & Fuhrmann, J. C. ClC-7 requires Ostm1 as a \u03b2-subunit to support bone resorption and lysosomal function. Nature 440, 220\u2013223 (2006).","journal-title":"Nature"},{"key":"1260_CR134","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nm842","volume":"9","author":"N Chalhoub","year":"2003","unstructured":"Chalhoub, N. et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat. Med. 9, 399\u2013406 (2003).","journal-title":"Nat. Med."},{"key":"1260_CR135","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/jbmr.4462","volume":"37","author":"J-Y Xue","year":"2022","unstructured":"Xue, J.-Y. et al. SLC4A2 deficiency causes a new type of osteopetrosis. J. Bone Miner. Res. 37, 226\u2013235 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR136","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","volume":"273","author":"BD Gelb","year":"1996","unstructured":"Gelb, B. D., Shi, G. P., Chapman, H. A. & Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273, 1236\u20131238 (1996).","journal-title":"Science"},{"key":"1260_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10663","volume":"6","author":"S Turan","year":"2022","unstructured":"Turan, S. et al. Dysosteosclerosis: clinical and radiological evolution reflecting genetic heterogeneity. JBMR Plus 6, e10663 (2022).","journal-title":"JBMR Plus"},{"key":"1260_CR138","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ajhg.2019.03.004","volume":"104","author":"L Guo","year":"2019","unstructured":"Guo, L. et al. Bi-allelic CSF1R mutations cause skeletal dysplasia of dysosteosclerosis-Pyle disease spectrum and degenerative encephalopathy with brain malformation. Am. J. Hum. Genet. 104, 925\u2013935 (2019).","journal-title":"Am. J. Hum. Genet."},{"key":"1260_CR139","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s10038-018-0447-6","volume":"63","author":"L Guo","year":"2018","unstructured":"Guo, L. et al. Dysosteosclerosis is also caused by TNFRSF11A mutation. J. Hum. Genet. 63, 769\u2013774 (2018).","journal-title":"J. Hum. Genet."},{"key":"1260_CR140","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1172\/JCI30328","volume":"117","author":"L Van Wesenbeeck","year":"2007","unstructured":"Van Wesenbeeck, L. et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J. Clin. Invest. 117, 919\u2013930 (2007).","journal-title":"J. Clin. Invest."},{"key":"1260_CR141","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1359\/jbmr.071107","volume":"23","author":"A Del Fattore","year":"2008","unstructured":"Del Fattore, A. et al. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J. Bone Miner. Res. 23, 380\u2013391 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR142","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/cr.2011.134","volume":"22","author":"Y Chen","year":"2012","unstructured":"Chen, Y. et al. A SNX10\/V-ATPase pathway regulates ciliogenesis in vitro and in vivo. Cell Res. 22, 333\u2013345 (2012).","journal-title":"Cell Res."},{"key":"1260_CR143","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/jmedgenet-2011-100520","volume":"49","author":"M Aker","year":"2012","unstructured":"Aker, M. et al. An SNX10 mutation causes malignant osteopetrosis of infancy. J. Med. Genet. 49, 221\u2013226 (2012).","journal-title":"J. Med. Genet."},{"key":"1260_CR144","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.omtm.2020.12.009","volume":"20","author":"I Moscatelli","year":"2021","unstructured":"Moscatelli, I. et al. Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal. Mol. Ther. Methods Clin. Dev. 20, 389\u2013397 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1260_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-023-00278-5","volume":"11","author":"CR Diegel","year":"2023","unstructured":"Diegel, C. R. et al. Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5. Bone Res. 11, 47 (2023).","journal-title":"Bone Res."},{"key":"1260_CR146","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR147","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04545554 (2024)."},{"key":"1260_CR148","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","volume":"39","author":"FH Glorieux","year":"2024","unstructured":"Glorieux, F. H. et al. Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J. Bone Miner. Res. 39, 1215\u20131228 (2024).","journal-title":"J. Bone Miner. Res."},{"key":"1260_CR149","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05125809 (2026)."},{"key":"1260_CR150","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","volume":"20","author":"I Grafe","year":"2014","unstructured":"Grafe, I. et al. Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta. Nat. Med. 20, 670\u2013675 (2014).","journal-title":"Nat. Med."},{"key":"1260_CR151","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152571","volume":"132","author":"I-W Song","year":"2022","unstructured":"Song, I.-W. et al. Targeting TGF-\u03b2 for treatment of osteogenesis imperfecta. J. Clin. Invest. 132, e152571 (2022).","journal-title":"J. Clin. Invest."},{"key":"1260_CR152","doi-asserted-by":"publisher","unstructured":"ISRCTN. Losartan for Older Adolescents and Adults with Osteogenesis Imperfecta https:\/\/doi.org\/10.1186\/ISRCTN13317811 (ISRCTN, 2026).","DOI":"10.1186\/ISRCTN13317811"},{"key":"1260_CR153","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte, M. P. et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N. Engl. J. Med. 366, 904\u2013913 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1260_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05734196 (2026)."},{"key":"1260_CR155","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel, E. A. et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393, 2416\u20132427 (2019).","journal-title":"Lancet"},{"key":"1260_CR156","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1210\/clinem\/dgad035","volume":"108","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta. J. Clin. Endocrinol. Metab. 108, 1787\u20131796 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1260_CR157","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03638128 (2022)."},{"key":"1260_CR158","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5966\/sctm.2013-0090","volume":"3","author":"C G\u00f6therstr\u00f6m","year":"2014","unstructured":"G\u00f6therstr\u00f6m, C. et al. Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cell Transl. Med. 3, 255\u2013264 (2014).","journal-title":"Stem Cell Transl. Med."},{"key":"1260_CR159","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll, E. S. et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J. Clin. Invest. 124, 491\u2013498 (2014).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01260-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:00:58Z","timestamp":1784030458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01260-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":159,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01260-x","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"30 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.P. has received research funding, travel grants and honoraria from Alexion, AstraZeneca, Kyowa Kirin and Ultragenyx. O.M. has received research funding, travel grants and honoraria from Alexion, Ascendis Pharma, Inozyme Pharma and Kyowa Kirin. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}